{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,26]],"date-time":"2026-08-26T05:20:28Z","timestamp":1787721628434,"version":"build-2784847793"},"reference-count":42,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,8,26]],"date-time":"2026-08-26T00:00:00Z","timestamp":1787702400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Cell. Infect. Microbiol."],"abstract":"<jats:sec>\n                    <jats:title>Objective<\/jats:title>\n                    <jats:p>The comprehensive safety profile and underlying molecular mechanisms of ivermectin-associated adverse drug reactions (ADRs) remain to be fully elucidated.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>We integrated pharmacovigilance data from the FDA Adverse Event Reporting System (FAERS) with network toxicology and transcriptomic validation. Disproportionality analyses were conducted on 1,421 ivermectin-related reports to detect signals at the System Organ Class (SOC) and Preferred Term (PT) levels. Network-based approaches, including protein-protein interaction (PPI) analysis and molecular docking, were employed to identify core toxicity targets, followed by ADMET property prediction.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Significant safety signals emerged for Eye disorders, Nervous system disorders, and General disorders. Frequently reported PTs included asthenia, headache, and pyrexia, alongside notable serious signals such as encephalopathy (ROR\u00a0=\u00a024.1) and toxic encephalopathy (ROR\u00a0=\u00a016.18). Network toxicology identified five core targets shared across key SOCs: EGFR, ERBB2, TGFB1, PIK3CA, and HSPG2. KEGG enrichment analysis highlighted pathways related to parasitic diseases, leukocyte migration, and endocrine regulation. Molecular docking confirmed high binding affinity between ivermectin components and EGFR (\u2264 -8.7 kcal\/mol). ADMET predictions indicated elevated risks for genotoxicity, ototoxicity, and skin sensitization.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Ivermectin-associated ADRs manifest across multiple organ systems, which are potentially associated with the modulation of predicted candidate targets including EGFR, ERBB2, TGFB1, PIK3CA, and HSPG2.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fcimb.2026.1938550","type":"journal-article","created":{"date-parts":[[2026,8,26]],"date-time":"2026-08-26T04:47:15Z","timestamp":1787719635000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Elucidating adverse drug reactions and underlying molecular mechanisms of ivermectin through pharmacovigilance and multi-omics analysis"],"prefix":"10.3389","volume":"16","author":[{"given":"Boyi","family":"Liu","sequence":"first","affiliation":[{"name":"The First Clinical College, Changsha Medical University","place":["Changsha, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaoze","family":"Chen","sequence":"additional","affiliation":[{"name":"College of Basic Medical Sciences, Naval Medical University","place":["Shanghai, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yishuo","family":"Wang","sequence":"additional","affiliation":[{"name":"The First Clinical College, Changsha Medical University","place":["Changsha, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hao","family":"Zhang","sequence":"additional","affiliation":[{"name":"College of Basic Medical Sciences, Naval Medical University","place":["Shanghai, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiao","family":"Liang","sequence":"additional","affiliation":[{"name":"The First Clinical College, Changsha Medical University","place":["Changsha, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xin","family":"Guan","sequence":"additional","affiliation":[{"name":"Department of Nuclear Medicine, First Hospital of Shanxi Medical University, Shanxi Medical University","place":["Taiyuan, Shanxi, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wenchao","family":"Zhang","sequence":"additional","affiliation":[{"name":"The First Clinical College, Changsha Medical University","place":["Changsha, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ao","family":"Han","sequence":"additional","affiliation":[{"name":"The First Clinical College, Changsha Medical University","place":["Changsha, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Danna","family":"Chen","sequence":"additional","affiliation":[{"name":"Department of Basic Medical Sciences, Changsha Medical University","place":["Changsha, Hunan, China"]},{"name":"Hunan Provincial University Key Laboratory of the Fundamental and Clinical Research on Functional Nucleic Acid, Changsha Medical University","place":["Changsha, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,8,26]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.3389\/fmed.2025.1703912","article-title":"Efficacy and safety of oral ivermectin versus benzyl benzoate for the treatment of scabies: a systematic review and meta-analysis of randomized controlled trials","volume":"12","author":"Abu-Zaid","year":"2025","journal-title":"Front. Med. (Lausanne)"},{"key":"B2","doi-asserted-by":"publisher","first-page":"112077","DOI":"10.1016\/j.cbi.2026.112077","article-title":"Mechanisms underlying DEHP\/MEHP-induced toxicity in multiple sclerosis: An integrated analysis combining network toxicology, bioinformatics, and in vivo experimental validation","volume":"433","author":"An","year":"2026","journal-title":"Chem. Biol. Interact."},{"key":"B3","doi-asserted-by":"publisher","first-page":"612","DOI":"10.1016\/j.therap.2021.10.001","article-title":"Mazzotti reaction: Ivermectin-associated polyarthritis after delayed scabies treatment. Case report and review of the literature","volume":"77","author":"Antonio","year":"2022","journal-title":"Therapie"},{"key":"B4","doi-asserted-by":"publisher","first-page":"382","DOI":"10.4269\/ajtmh.17-0042","article-title":"Serious neurological adverse events after ivermectin-Do they occur beyond the indication of onchocerciasis","volume":"98","author":"Chandler","year":"2018","journal-title":"Am. J. Trop. Med. Hyg."},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.3389\/fncel.2022.941031","article-title":"Putative COVID-19 therapies imatinib, lopinavir, ritonavir, and ivermectin cause hair cell damage: A targeted screen in the zebrafish lateral line","volume":"16","author":"Coffin","year":"2022","journal-title":"Front. Cell. Neurosci."},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2024.1329409","article-title":"From genomic spectrum of NTRK genes to adverse effects of its inhibitors, a comprehensive genome-based and real-world pharmacovigilance analysis","volume":"15","author":"Cui","year":"2024","journal-title":"Front. Pharmacol."},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.3389\/fmed.2019.00284","article-title":"New frontiers for molecular pathology","volume":"6","author":"Domagala-Kulawik","year":"2019","journal-title":"Front. Med. (Lausanne)"},{"key":"B8","doi-asserted-by":"publisher","first-page":"S8","DOI":"10.1186\/1475-2883-2-s1-s8","article-title":"Ivermectin: does P-glycoprotein play a role in neurotoxicity","author":"Edwards","year":"2003","journal-title":"Filaria J."},{"key":"B9","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1076\/0928-6586(200003)711-2ft027","article-title":"Ocular findings after ivermectin treatment of patients with high Loa loa microfilaremia","volume":"7","author":"Fobi","year":"2000","journal-title":"Ophthalmic Epidemiol."},{"key":"B10","doi-asserted-by":"publisher","first-page":"e341","DOI":"10.1016\/s1473-3099(22)00369-3","article-title":"Ivermectin and albendazole coadministration: opportunities for strongyloidiasis control","volume":"22","author":"Gandasegui","year":"2022","journal-title":"Lancet Infect. Dis."},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1007\/s00210-026-05292-y","article-title":"Real-world safety signals of baricitinib and in silico exploration of a potential mechanism underlying herpes zoster: a multidisciplinary analysis","volume":"399","author":"He","year":"2026","journal-title":"Naunyn Schmiedebergs Arch. Pharmacol"},{"key":"B12","doi-asserted-by":"publisher","first-page":"341","DOI":"10.1038\/nrc1609","article-title":"ERBB receptors and cancer: the complexity of targeted inhibitors","volume":"5","author":"Hynes","year":"2005","journal-title":"Nat. Rev. Cancer"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1002\/pds.70344","article-title":"Trends and patterns of adverse drug reaction reporting in Sierra Leone: A retrospective analysis of VigiFlow data (2008-2022)","volume":"35","author":"Jalloh","year":"2026","journal-title":"Pharmacoepidemiol. Drug Saf."},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1016\/j.arr.2022.101791","article-title":"Implicative role of epidermal growth factor receptor and its associated signaling partners in the pathogenesis of Alzheimer's disease","volume":"83","author":"Jayaswamy","year":"2023","journal-title":"Ageing Res. Rev."},{"key":"B15","doi-asserted-by":"publisher","first-page":"265","DOI":"10.1186\/s13046-019-1251-7","article-title":"Ivermectin reverses the drug resistance in cancer cells through EGFR\/ERK\/Akt\/NF-\u03baB pathway","volume":"38","author":"Jiang","year":"2019","journal-title":"J. Exp. Clin. Cancer Res."},{"key":"B16","doi-asserted-by":"publisher","first-page":"137","DOI":"10.21203\/rs.3.rs-2879768\/v1","article-title":"Onchocerca volvulus microfilariae in the anterior chambers of the eye and ocular adverse events after a single dose of 8 mg moxidectin or 150 \u00b5g\/kg ivermectin: results of a randomized double-blind Phase 3 trial in the Democratic Republic of the Congo, Ghana and Liberia","volume":"17","author":"Kanza","year":"2024","journal-title":"Parasit Vectors"},{"key":"B17","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1016\/j.jri.2023.104065","article-title":"Immune system adaptation during gender-affirming testosterone treatment","volume":"633","author":"Lakshmikanth","year":"2024","journal-title":"Nature"},{"key":"B18","doi-asserted-by":"publisher","first-page":"1626","DOI":"10.1002\/lary.29424","article-title":"A narrative review of pharmacologic treatments for COVID-19: Safety considerations and ototoxicity","volume":"131","author":"Little","year":"2021","journal-title":"Laryngoscope"},{"key":"B19","doi-asserted-by":"publisher","first-page":"1426","DOI":"10.1001\/jama.2021.3071","article-title":"Effect of ivermectin on time to resolution of symptoms among adults with mild COVID-19: A randomized clinical trial","volume":"325","author":"L\u00f3pez-Medina","year":"2021","journal-title":"Jama"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtho.2026.103709","article-title":"Lung cancer in never smokers: Genetics, epidemiology, environmental exposures, and distinct immune landscape","volume":"21","author":"Lu","year":"2026","journal-title":"J. Thorac. Oncol."},{"key":"B21","doi-asserted-by":"publisher","first-page":"2787","DOI":"10.1200\/jco.2003.01.504","article-title":"Status of epidermal growth factor receptor antagonists in the biology and treatment of cancer","volume":"21","author":"Mendelsohn","year":"2003","journal-title":"J. Clin. Oncol."},{"key":"B22","doi-asserted-by":"publisher","first-page":"536","DOI":"10.1016\/j.jiac.2023.12.012","article-title":"Efficacy and safety of ivermectin in patients with mild COVID-19 in Japan and Thailand","volume":"30","author":"Mikamo","year":"2024","journal-title":"J. Infect. Chemother."},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1002\/prp2.541","article-title":"Individualized medicine: Sex, hormones, genetics, and adverse drug reactions","volume":"7","author":"Moyer","year":"2019","journal-title":"Pharmacol. Res. Perspect."},{"key":"B24","doi-asserted-by":"publisher","first-page":"12089","DOI":"10.3390\/ijms252212089","article-title":"The effect of metformin and hydrochlorothiazide on cytochrome P450 3A4 metabolism of ivermectin: Insights from in silico experimentation","volume":"25","author":"Mtambo","year":"2024","journal-title":"Int. J. Mol. Sci."},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijantimicag.2025.107676","article-title":"Adverse effects of posaconazole on adrenal steroid biosynthesis: An integrative approach using FAERS-based pharmacovigilance and systematic review with meta-analysis of randomised controlled trials","volume":"67","author":"Nakano","year":"2026","journal-title":"Int. J. Antimicrob. Agents"},{"key":"B26","doi-asserted-by":"publisher","first-page":"699","DOI":"10.1172\/jci130819","article-title":"Ivermectin inhibits HSP27 and potentiates efficacy of oncogene targeting in tumor models","volume":"130","author":"Nappi","year":"2020","journal-title":"J. Clin. Invest."},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaad.2026.01.061","article-title":"Cutaneous toxicities of small molecules in targeted cancer therapy part I - Mechanisms of toxicity","author":"Nykaza","year":"2026","journal-title":"J. Am. Acad. Dermatol"},{"key":"B28","doi-asserted-by":"publisher","first-page":"1207","DOI":"10.1016\/s0140-6736(17)32844-1","article-title":"Single dose moxidectin versus ivermectin for Onchocerca volvulus infection in Ghana, Liberia, and the Democratic Republic of the Congo: a randomised, controlled, double-blind phase 3 trial","volume":"392","author":"Opoku","year":"2018","journal-title":"Lancet"},{"key":"B29","doi-asserted-by":"publisher","first-page":"1070","DOI":"10.1007\/s11912-025-01704-z","article-title":"Ivermectin in cancer treatment: Should healthcare providers caution or explore its therapeutic potential","volume":"27","author":"Patel","year":"2025","journal-title":"Curr. Oncol. Rep."},{"key":"B30","doi-asserted-by":"publisher","first-page":"234","DOI":"10.1007\/s11011-025-01657-z","article-title":"Ivermectin's neuroprotective effects decrease with prolonged use after cerebral ischemia\/reperfusion","volume":"40","author":"Rezaei","year":"2025","journal-title":"Metab. Brain Dis."},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.1016\/j.clae.2024.102343","article-title":"A systematic review of the potential treatment effects of topical epidermal growth factor for ocular surface disorders","volume":"48","author":"Sanie-Jahromi","year":"2025","journal-title":"Cont. Lens Anterior Eye"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtho.2026.103711","article-title":"Targeting MET in EGFR-mutated NSCLC","volume":"21","author":"Saw","year":"2026","journal-title":"J. Thorac. Oncol."},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.1016\/j.coph.2025.102574","article-title":"Ivermectin and non-parasitic disorders: An update","volume":"85","author":"Seyyedabadi","year":"2025","journal-title":"Curr. Opin. Pharmacol."},{"key":"B34","doi-asserted-by":"publisher","first-page":"1419","DOI":"10.1039\/d5np00007f","article-title":"Natural products in antiparasitic drug discovery: advances, opportunities and challenges","volume":"42","author":"Shang","year":"2025","journal-title":"Nat. Prod. Rep."},{"key":"B35","doi-asserted-by":"publisher","first-page":"2696","DOI":"10.1097\/js9.0000000000003620","article-title":"Decoding tamoxifen on idiopathic pulmonary fibrosis: integrating network toxicology and multi-omics","volume":"112","author":"Sun","year":"2026","journal-title":"Int. J. Surg."},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.1016\/j.psj.2026.106890","article-title":"Integrated network toxicology and molecular docking revealed that 2-ethylhexyldiphenylphosphoric acid induces nephrotoxicity in chickens by activating the ROS\/JNK pathway","volume":"105","author":"Tang","year":"2026","journal-title":"Poult. Sci."},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2026.1796154","article-title":"Real-world pharmacovigilance and molecular mechanisms of fruquintinib: SRC and STAT3 as potential off-target mediators of proteinuria","volume":"17","author":"Xu","year":"2026","journal-title":"Front. Pharmacol."},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaut.2026.103553","article-title":"Divergent safety profiles of TNF inhibitors in pregnancy: a comprehensive pharmacovigilance analysis of the FAERS database","volume":"160","author":"Yan","year":"2026","journal-title":"J. Autoimmun."},{"key":"B39","doi-asserted-by":"publisher","first-page":"553","DOI":"10.1038\/nrc3309","article-title":"The ERBB network: at last, cancer therapy meets systems biology","volume":"12","author":"Yarden","year":"2012","journal-title":"Nat. Rev. Cancer"},{"key":"B40","doi-asserted-by":"publisher","DOI":"10.1002\/jat.70166","article-title":"Ivermectin toxicity in humans and animals: Clinical spectrum, mechanisms, and management","volume":"46","author":"Yilmaz","year":"2026","journal-title":"J. Appl. Toxicol"},{"key":"B41","doi-asserted-by":"publisher","first-page":"98","DOI":"10.1007\/s42764-025-00155-x","article-title":"Efficient analysis of the toxicity and mechanisms of Hexaconazole and two other triazole fungicides: insights from integrated network toxicology, molecular docking and bioinformatics data","volume":"6","author":"Zhu","year":"2025","journal-title":"Genome Instability Dis."},{"key":"B42","doi-asserted-by":"publisher","first-page":"881","DOI":"10.1080\/02770903.2024.2449231","article-title":"Association and mechanism of montelukast on sleep disorders: insights from NHANES 2005-2018 data analysis and a network pharmacology study","volume":"62","author":"Zhu","year":"2025","journal-title":"J. Asthma"}],"container-title":["Frontiers in Cellular and Infection Microbiology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fcimb.2026.1938550\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,26]],"date-time":"2026-08-26T04:47:19Z","timestamp":1787719639000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fcimb.2026.1938550\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,26]]},"references-count":42,"alternative-id":["10.3389\/fcimb.2026.1938550"],"URL":"https:\/\/doi.org\/10.3389\/fcimb.2026.1938550","relation":{},"ISSN":["2235-2988"],"issn-type":[{"value":"2235-2988","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8,26]]},"article-number":"1938550"}}